International Publisher of Science, Technology and Medicine

 
 
Share this
 
 
 
Track Your Manuscript
 
 
 
 
Journal of Clinical & Experimental Oncology
Editor-in-Chief: Mark A. Brown, PhD
 Colorado State University, USA
ISSN: 2324-9110
Frequency: Quarterly
 
The Journal of Clinical & Experimental Oncology (JCEOG) promotes rigorous research that makes a significant contribution in advancing knowledge for cancer diagnosis and therapy. The journal includes all major themes pertaining to medical oncology, surgery, radiotherapy and pediatric oncology.
 
Clinical & Experimental Oncology is a subscription based journal that provides a range of options to purchase our articles and also permits unlimited Internet Access to complete Journal content. It accepts research, review papers, online letters to the editors & brief comments on previously published articles or other relevant findings in SciTechnol. Articles submitted by authors are evaluated by a group of peer review experts in the field and ensures that the published articles are of high quality, reflect solid scholarship in their fields, and that the information they contain is accurate and reliable.
 
The journal is using Editorial Manager System for quality in review process. Editorial Manager is an online manuscript submission, review and tracking systems. Review processing is performed by the editorial board members of Journal of Clinical & Experimental Oncology or outside experts; at least two independent reviewers approval followed by editor approval is required for acceptance of any citable manuscript. Authors may submit manuscripts and track their progress through the system, hopefully to publication. Reviewers can download manuscripts and submit their opinions to the editor. Editors can manage the whole submission/review/revise/publish process.;
 
Submit manuscript at http://www.editorialmanager.com/scitechnol/ or send as an e-mail attachment to the Editorial Office at editor.jceog@scitechnol.com or editor.jceog@scitechnol.org
 
 
Current Issue
p53 Gene Inactivation Modulate Methylenetetrahydrofolate C677T Gene Polymorphism Associated Risk Factor for the Development of Cervical Carcinoma -A Tissue specific Genetic Heterogeneity   Research Article
GK Singh, Ajit K Saxena, Anjula, Garima, S Pandey and LK Pandey
J Clin Exp Oncol 2013, 2:4    doi: 10.4172/2324-9110.1000114
 Preview

p53 Gene Inactivation Modulate Methylenetetrahydrofolate C677T Gene Polymorphism Associated Risk Factor for the Development of Cervical Carcinoma -A Tissue specific Genetic Heterogeneity

Inconsistently, epidemiological studies reveals that folate regulate a significant role in DNA synthesis and etiopathology of cervical cancer in women. Folate, an essential dietary component require for DNA methylation during cell proliferation. Methylenetetrahydrofolate reductase (MTHFR) catalyzes the synthesis of 5-methylenetetrahydrofolate involved in the methylation of homocysteine to methionine. A common substitution of this enzyme gene variant 677 C → T (Ala → Val) shown to reduced activity results mild hyperhomocysteinemia. We have collected the blood sample from those patients having lack of infection form human papilloma virus (HPV).

|  Full Text |   PDF   
Survivin and Livin with Angiogenesis in Cancer   Research Article
Mutlu Dogan
J Clin Exp Oncol 2013, 2:4    doi: 10.4172/2324-9110.1000115
 Preview

Survivin and Livin with Angiogenesis in Cancer

Tumor promotion and progression depends on a complex interaction between cellular signaling pathways, apoptosis, angiogenesis and other mechanisms. Understanding these mechanisms and their interactions led to the development of targeted therapies such as antiangiogenic agents and mTOR inhibitors in cancer. In recent years, inhibitors of apoptosis proteins (IAP) like survivin and livin seem promising as new targets for cancer therapy. In this report, the role of survivin and livin with angiogenesis will be discussed.

|  Full Text |   PDF   
Encapsulated Minimally Invasive Epimyoepithelial Carcinoma of Submandibular Gland - A New Entity?? With Review of Literature   Research Article
Shelly Arora, Aadithya B Urs and Nita Khurana
J Clin Exp Oncol 2013, 2:4    doi: 10.4172/2324-9110.1000116
 Preview

Encapsulated Minimally Invasive Epimyoepithelial Carcinoma of Submandibular Gland - A New Entity?? With Review of Literature

Epimyoepithelial carcinoma (EMC) is a rare low-grade salivary gland malignancy comprising of 1% of all the salivary glands tumors. EMC is a rare tumor when involving submandibular gland (8.6%) as compared to parotid gland (62.1%). A thorough pubmed literature search retrieved only 17 cases of EMC involving submandibular gland since 1972. EMC can present in classical pattern characterised by biphasic cell population with inner layer of cuboidal to columnar cells and outer layer of myoepithelial cells. Encapsulated minimally invasive epimyoepithelial carcinoma is a recently coined terminology by Seethala et al. To the best of our knowledge, this is the first case of encapsulated minimally invasive EMC of submandibular salivary gland discussed in the literature. The present paper highlights the review of literature of EMC involving submandibular salivary gland, histomorphological spectrum and diagnostic differentiation from other salivary gland tumors.

|  Full Text |   PDF   
“REACTIONS” - A Memorable Patient   Commentary
Vittal S R Rao, S Sugunendran, and Kevin Wedgwood
J Clin Exp Oncol 2013, 2:4    doi: 10.4172/2324-9110.1000117
 Preview

“REACTIONS” - A Memorable Patient

All of us at some point in our careers get enlightened by our patients regarding even the subtle aspects of the practice of clinical medicine. In one of our routine hectic outpatients, we had this routine referral regarding a lady in her mid fifties with carcinoid syndrome. As the lady was being ushered into the examination bays, I frantically tried to recap the classical symptoms associated with the condition so that I can touch base with the patient before deciding about further management. Mustering what I could from my memory, I went to greet my patient and initiate the consultation. Before I could proceed to elicit the symptoms which I could recollect, the pleasant lady thrust into my hands a neatly typed paper aptly titled ‘Re-actions’ to highlight her symptoms.

|  Full Text |   PDF